Company Overview and News

 
Hindustan Zinc#39;s mined metal output grows 6% to 2.32 lakh tonnes

2018-10-13 moneycontrol
Vedanta Group firm Hindustan Zinc said its mined metal production grew 6 percent to 2,32,000 tonnes in the second quarter of the ongoing fiscal.
HNDZY 500188 HINDZINC

 
Hindustan Zinc Limited - Updates

2018-10-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HNDZY 500188 HINDZINC

 
Metal stocks fall with Vedanta plunging 11%, hits new 52-week low; Hindalco, NALCO shed 5-9%

2018-10-08 moneycontrol
The Indian stock market has once again plunged this afternoon with the Nifty50 shedding 114 points, trading at 10,202 while the Sensex has lost 391 points at 33,985.
HINDCOPPER HINDALCO 500228 513599 HNDZY 533278 JSWSTEEL HNDNF 500470 TTST TATASTEEL TATLY CLNDY COALINDIA 500440 500188 HINDZINC

 
Getting difficult to find, retain Maths, Science teachers in village schools, says Vice President M Venkaiah Naidu

2018-09-29 financialexpress
Vice President M Venkaiah Naidu said Saturday it was becoming increasingly difficult to retain good science and mathematics teachers in village schools and these subjects were not being offered in the higher classes in such schools.
HNDZY 500188 HINDZINC

 
Hindustan Zinc shares correct after Macquarie downgrades and cuts target price

2018-09-25 moneycontrol
Hindustan Zinc share price fell 1.5 percent intraday Tuesday after global research firm Macquarie downgraded the stock and also slashed target price.
HNDZY 500188 HINDZINC

 
D-Street Buzz: Nifty metal outperforms led by JSW Steel; Dish TV down 6%, BoB most active

2018-09-19 moneycontrol
The Indian benchmark indices continues to trade on a positive note this Wednesday afternoon with the Nifty50 up 21 points and is trading at 11,300 while the Sensex is trading higher by 53 points at 37,343.
HINDCOPPER KOHINOOR MUTHOOTFIN PGEL 500325 500228 RELIANCE 532617 HNDZY HFCL 533398 NAUKRI 532777 533137 HCL-INSYS DEN 532221 500470 SONATSOFTW RIGD 500179 JSL GAILF BEL RLNIY SBAZ BHQRY HINDALCO 532508 533581 513599 JETAIRWAYS JSWSTEEL 533104 512559 HNDNF 500183 TTST TATASTEEL TATLY GAILY DCMSHRIRAM 500049 GLOBUSSPR 500440 500188 HINDZINC 523367

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...